Adaptive Biotechnologies (NASDAQ:ADPT) Insider Francis Lo Sells 44,838 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 44,838 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $22.59, for a total value of $1,012,890.42. Following the completion of the transaction, the insider directly owned 230,713 shares in the company, valued at $5,211,806.67. This trade represents a 16.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Francis Lo also recently made the following trade(s):

• On Wednesday, July 1st, Francis Lo sold 51,004 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $22.45, for a total value of $1,145,039.80.
• On Thursday, June 4th, Francis Lo sold 39,741 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $17.49, for a total value of $695,070.09.
• On Wednesday, April 8th, Francis Lo sold 22,564 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.07, for a total value of $340,039.48.

Adaptive Biotechnologies Stock Performance

Shares of NASDAQ:ADPT opened at $21.50 on Tuesday. The business’s 50-day simple moving average is $16.24 and its 200 day simple moving average is $15.90. The company has a market cap of $3.44 billion, a P/E ratio of -65.15 and a beta of 2.07. Adaptive Biotechnologies Corporation has a one year low of $9.96 and a one year high of $22.80.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The firm had revenue of $70.87 million during the quarter, compared to analysts’ expectations of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.Adaptive Biotechnologies’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.20) EPS. Analysts predict that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current year.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd acquired a new position in Adaptive Biotechnologies in the fourth quarter worth about $28,000. EverSource Wealth Advisors LLC increased its holdings in Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after buying an additional 1,565 shares during the last quarter. Assetmark Inc. raised its stake in Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after buying an additional 2,708 shares in the last quarter. T. Rowe Price Investment Management Inc. acquired a new stake in Adaptive Biotechnologies during the fourth quarter valued at approximately $51,000. Finally, Strive Financial Group LLC bought a new position in Adaptive Biotechnologies during the 4th quarter worth approximately $52,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Analyst Ratings Changes

ADPT has been the topic of several analyst reports. TD Cowen lifted their price target on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Guggenheim raised their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Morgan Stanley dropped their target price on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. BTIG Research reiterated a “buy” rating and issued a $22.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday, June 17th. Finally, JPMorgan Chase & Co. reduced their price target on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $20.50.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.